Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$8.70
+11.0%		$6.97
$1.85
▼
$8.70
$117.47M0.08100,798 shs112,145 shs
Soligenix Inc. stock logo
SNGX
Soligenix
$0.41
+0.1%		$0.38
$0.28
▼
$3.36
$6M1.93232,862 shs216,952 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
+2.48%+2.08%+18.61%+35.88%+138.30%
Soligenix Inc. stock logo
SNGX
Soligenix
+0.92%+6.16%+9.00%-21.11%-88.03%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$8.70
+11.0%		$6.97
$1.85
▼
$8.70
$117.47M0.08100,798 shs112,145 shs
Soligenix Inc. stock logo
SNGX
Soligenix
$0.41
+0.1%		$0.38
$0.28
▼
$3.36
$6M1.93232,862 shs216,952 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
+2.48%+2.08%+18.61%+35.88%+138.30%
Soligenix Inc. stock logo
SNGX
Soligenix
+0.92%+6.16%+9.00%-21.11%-88.03%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
1.00
SellN/AN/A
Soligenix Inc. stock logo
SNGX
Soligenix
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest SNGX and CPIX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Soligenix Inc. stock logo
SNGX
Soligenix
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$44.52M2.93$0.41 per share21.38$1.14 per share7.63
Soligenix Inc. stock logo
SNGX
Soligenix
$120K50.03N/AN/A$0.45 per share0.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
-$2.84M-$0.71N/AN/AN/A-34.40%-28.81%-9.25%11/3/2026 (Estimated)
Soligenix Inc. stock logo
SNGX
Soligenix
-$11.08M-$0.98N/AN/AN/AN/A-180.25%-107.46%11/6/2026 (Estimated)

Latest SNGX and CPIX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2026Q2 2026
Soligenix Inc. stock logo
SNGX
Soligenix
-$0.1550-$0.12+$0.0350-$0.12N/AN/A
8/4/2026Q2 2026
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
-$0.13-$0.20-$0.07-$0.29$8.50 million$0.17 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
N/AN/AN/AN/AN/A
Soligenix Inc. stock logo
SNGX
Soligenix
N/AN/AN/AN/AN/A

Latest SNGX and CPIX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/13/2026
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$1.507/23/20267/31/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
N/A
0.96
0.96
Soligenix Inc. stock logo
SNGX
Soligenix
N/A
2.77
2.77

Institutional Ownership

CompanyInstitutional Ownership
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
15.51%
Soligenix Inc. stock logo
SNGX
Soligenix
3.60%

Insider Ownership

CompanyInsider Ownership
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
42.07%
Soligenix Inc. stock logo
SNGX
Soligenix
1.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
8014.98 million8.68 millionOptionable
Soligenix Inc. stock logo
SNGX
Soligenix
2014.82 million14.54 millionNot Optionable

Recent News About These Companies

Q3 Earnings Estimate for Soligenix Issued By Zacks Research
August 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30965103
SNGX: Applying for Vaccine Development Funding for Ebola Vaccine
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/sngx-applying-vaccine-development-funding-112500628.html
Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results
August 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/soligenix-announces-recent-updates-and-second-quarter-2026-financial-results-302845724.html
Soligenix Expands At-the-Market Equity Offering Capacity
June 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/soligenix-expands-at-the-market-equity-offering-capacity?utm_source=marketbeat.com&utm_medium=referral
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
June 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/soligenix-applying-for-vaccine-development-funding-for-bundibugyo-ebola-vaccine-302793388.html
Soligenix Expands At-The-Market Equity Financing Capacity
May 28, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/soligenix-expands-at-the-market-equity-financing-capacity?utm_source=marketbeat.com&utm_medium=referral
SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy
May 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/sngx-stock-more-doubles-pre-112801471.html
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
May 26, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/suitability-of-vaccine-platform-for-bundibugyo-virus-cause-of-the-ebola-outbreak-in-congo-302780813.html
SOLIGENIX, INC.: Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
May 8, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68439993-soligenix-inc-soligenix-announces-recent-updates-and-first-quarter-2026-financial-results-008.htm
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
May 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/soligenix-announces-recent-updates-and-first-quarter-2026-financial-results-302766364.html
SNGX stock slumps to record low after lymphoma trial fails – all eyes now on Behçet’s disease treatment
April 29, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/sngx-stock-slumps-to-record-low-after-lymphoma-trial-fails-all-eyes-now-on-beh%C3%A7et-s-disease-treatment/ar-AA21Vlpj
SNGX phase 3 trial halted on HyBryte
April 29, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/sngx-phase-3-trial-halted-on-hybryte/ar-AA21VuWj
SOLIGENIX, INC.: Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte in Treatment of Cutaneous T-Cell Lymphoma
April 28, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-04/68326767-soligenix-inc-soligenix-announces-interim-results-from-the-phase-3-flash2-trial-evaluating-hybryte-in-treatment-of-cutaneous-t-cell-lymphoma-008.htm
SNGX phase 3 trial halted — HyBryte setback puts strategy in question
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/sngx-phase-3-trial-halted-hybryte-setback-puts-strategy-in-question/ar-AA21VuWj
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
April 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/soligenix-announces-interim-results-from-the-phase-3-flash2-trial-evaluating-hybryte-in-treatment-of-cutaneous-t-cell-lymphoma-302754503.html
Soligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach
April 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/soligenix-sngx-highlights-patient-centric-190000456.html
Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach
April 23, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/30963/soligenix-nasdaq-sngx-highlights-patient-centric-drug-development-strategy-through-reformulation-approach/
Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status
April 20, 2026  |  financial-news.co.ukhttps://www.financial-news.co.uk/soligenix-nasdaq-sngx-strengthens-pipeline-as-european-commission-grants-sgx945-orphan-status/
Soligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status
April 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/soligenix-sngx-strengthens-pipeline-european-182338961.html
Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results
April 17, 2026  |  financial-news.co.ukhttps://www.financial-news.co.uk/soligenix-nasdaq-sngx-advances-ctcl-research-with-interim-analysis-comparative-study-results/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cumberland Pharmaceuticals stock logo

Cumberland Pharmaceuticals NASDAQ:CPIX

$8.70 +0.86 (+10.97%)
Closing price 04:00 PM Eastern
Extended Trading
$8.72 +0.02 (+0.17%)
As of 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Soligenix stock logo

Soligenix NASDAQ:SNGX

$0.41 +0.00 (+0.10%)
Closing price 04:00 PM Eastern
Extended Trading
$0.40 0.00 (-0.02%)
As of 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas